Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) EBT Margin (2016 - 2025)

Historic EBT Margin for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to 88.48%.

  • Arcadia Biosciences' EBT Margin fell 115800.0% to 88.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 99.59%, marking a year-over-year decrease of 699700.0%. This contributed to the annual value of 85.41% for FY2024, which is 340500.0% up from last year.
  • Arcadia Biosciences' EBT Margin amounted to 88.48% in Q3 2025, which was down 115800.0% from 34.43% recorded in Q2 2025.
  • In the past 5 years, Arcadia Biosciences' EBT Margin ranged from a high of 243.33% in Q2 2023 and a low of 644.32% during Q1 2021
  • In the last 5 years, Arcadia Biosciences' EBT Margin had a median value of 98.42% in 2022 and averaged 152.42%.
  • Examining YoY changes over the last 5 years, Arcadia Biosciences' EBT Margin showed a top increase of 29798600bps in 2021 and a maximum decrease of -4500000bps in 2021.
  • Arcadia Biosciences' EBT Margin (Quarter) stood at 320.95% in 2021, then soared by 117bps to 54.49% in 2022, then plummeted by -205bps to 57.27% in 2023, then crashed by -479bps to 331.33% in 2024, then surged by 73bps to 88.48% in 2025.
  • Its EBT Margin stands at 88.48% for Q3 2025, versus 34.43% for Q2 2025 and 44.17% for Q1 2025.